Loading clinical trials...
Loading clinical trials...
A Randomized, Double-blind, Parallel, Placebo-controlled, Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effect of AMG 557 in Systemic Lupus Erythematosus (SLE) Subjects With Active Lupus Arthritis
This is a multicenter, randomized, double-blind, parallel, placebo-controlled, multiple dose study that will enroll approximately 40 systemic lupus erythematosus subjects with active lupus arthritis.
Age
18 - 65 years
Sex
ALL
Healthy Volunteers
No
Research Site
Los Angeles, California, United States
Research Site
San Leandro, California, United States
Research Site
Danbury, Connecticut, United States
Research Site
Manhasset, New York, United States
Research Site
St Leonards, New South Wales, Australia
Research Site
Odense, Denmark
Research Site
Lille, France
Research Site
Berlin, Germany
Research Site
Kuala Lumpur, Kuala Lumpur, Malaysia
Research Site
Kuching, Sarawak, Malaysia
Start Date
June 1, 2012
Primary Completion Date
March 1, 2016
Completion Date
March 1, 2016
Last Updated
January 24, 2017
20
ACTUAL participants
AMG 557
DRUG
Matching Placebo
DRUG
Lead Sponsor
Amgen
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions